Literature DB >> 21960790

Overcoming adherence issues in ulcerative colitis.

Sunanda V Kane1.   

Abstract

Ulcerative colitis (UC) is a chronic condition requiring lifelong medication to minimize the incidence of symptomatic flares. Nevertheless, studies have shown that a large proportion of patients are nonadherent to their prescribed therapeutic regimen. This review examines studies of patient adherence to 5-aminosalicylic acid (5-ASA) therapy in real world settings and considers the reasons that patients do not adhere to medication. Patients offer numerous reasons for not taking medication as prescribed; however, neither clinical nor community studies have consistently identified the same groups of patients as being high risk for poor adherence. Indeed, the problem of nonadherence is complex and requires a combination of strategies to be improved. Physicians, physician assistants, and nurse practitioners need to take the time to explain the importance of continual therapy, even when patients feel well, and should engage patients in a discussion to aid in the understanding of their nonadherence. Then, healthcare providers can determine how to best amend the regimen to improve adherence. As taking several tablets several times daily may be confusing or difficult for patients, higher strength 5-ASA formulations that require fewer daily doses have the potential to enhance patient adherence as part of an overall management strategy.

Entities:  

Keywords:  5-ASA; Adherence; convenience; ulcerative colitis

Year:  2007        PMID: 21960790      PMCID: PMC3104162     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  25 in total

Review 1.  Etiology and pathogenesis of inflammatory bowel disease.

Authors:  C Schmidt; A Stallmach
Journal:  Minerva Gastroenterol Dietol       Date:  2005-06

2.  Why do patients with ulcerative colitis relapse?

Authors:  S A Riley; V Mani; M J Goodman; S Lucas
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

3.  Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.

Authors:  Stephen B Hanauer; William J Sandborn; Asher Kornbluth; Seymour Katz; Michael Safdi; Scott Woogen; Gino Regalli; Chyon Yeh; Nancy Smith-Hall; Funmilay Ajayi
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

Review 4.  Compliance with treatment regimens in chronic asymptomatic diseases.

Authors:  N H Miller
Journal:  Am J Med       Date:  1997-02-17       Impact factor: 4.965

5.  Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.

Authors:  E V Loftus; M D Silverstein; W J Sandborn; W J Tremaine; W S Harmsen; A R Zinsmeister
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

Review 6.  Mesalamine delivery systems: do they really make much difference?

Authors:  Altamash I Qureshi; Russell D Cohen
Journal:  Adv Drug Deliv Rev       Date:  2005-01-06       Impact factor: 15.470

7.  Compliance to therapy in patients on a maintenance dose of sulfasalazine.

Authors:  P A van Hees; J H van Tongeren
Journal:  J Clin Gastroenterol       Date:  1982-08       Impact factor: 3.062

8.  Patient nonadherence to medication in inflammatory bowel disease.

Authors:  Maida J Sewitch; Michal Abrahamowicz; Alan Barkun; Alain Bitton; Gary E Wild; Albert Cohen; Patricia L Dobkin
Journal:  Am J Gastroenterol       Date:  2003-07       Impact factor: 10.864

9.  Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease.

Authors:  Jau-Min Wong; Shu-Chen Wei
Journal:  J Formos Med Assoc       Date:  2003-09       Impact factor: 3.282

10.  Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa.

Authors:  G Rogler; K Brand; D Vogl; S Page; R Hofmeister; T Andus; R Knuechel; P A Baeuerle; J Schölmerich; V Gross
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

View more
  6 in total

1.  Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group Trial.

Authors:  Mitsuro Chiba; Kunio Nakane; Tsuyotoshi Tsuji; Satoko Tsuda; Hajime Ishii; Hideo Ohno; Kenta Watanabe; Mai Ito; Masafumi Komatsu; Koko Yamada; Takeshi Sugawara
Journal:  Perm J       Date:  2018

Review 2.  Adherence in ulcerative colitis: an overview.

Authors:  Anna Testa; Fabiana Castiglione; Olga Maria Nardone; Giorgio L Colombo
Journal:  Patient Prefer Adherence       Date:  2017-02-22       Impact factor: 2.711

3.  Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.

Authors:  Aaron Yarlas; Geert D'Haens; Mary Kaye Willian; Megan Teynor
Journal:  Inflamm Bowel Dis       Date:  2018-01-18       Impact factor: 5.325

4.  Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease.

Authors:  Sanjeevani K Tomar; Saurabh Kedia; Namrata Singh; Ashish D Upadhyay; Nagesh Kamat; Sawan Bopanna; Dawesh P Yadav; Sandeep Goyal; Saransh Jain; Govind Makharia; Vineet Ahuja
Journal:  JGH Open       Date:  2019-03-18

5.  Ulcerative colitis in the postpartum period.

Authors:  Mitsuro Chiba; Tsuyotoshi Tsuji; Masafumi Komatsu; Hiroyuki Watanabe; Masato Takahashi
Journal:  Autops Case Rep       Date:  2020-09-02

6.  Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase.

Authors:  Akira Madarame; Masakatsu Fukuzawa; Yoshiya Yamauchi; Shin Kono; Akihiko Sugimoto; Hayato Yamaguchi; Takashi Morise; Yohei Koyama; Kumiko Uchida; Maya Suguro; Taisuke Matsumoto; Kagawa Yasuyuki; Takashi Kawai; Takao Itoi
Journal:  PLoS One       Date:  2021-08-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.